BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yang X, Wang JX, Han SX, Gao CP. High dose dual therapy versus bismuth quadruple therapy for Helicobacter pylori eradication treatment: A systematic review and meta-analysis. Medicine (Baltimore). 2019;98:e14396. [PMID: 30762742 DOI: 10.1097/md.0000000000014396] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 9.3] [Reference Citation Analysis]
Number Citing Articles
1 Fernández-Salazar L, Campillo A, Rodrigo L, Pérez-Aisa Á, González-Santiago JM, Segarra Ortega X, Denkovski M, Brglez Jurecic N, Bujanda L, Gómez Rodríguez BJ, Ortuño J, Georgopoulos S, Jonaitis L, Puig I, P Nyssen O, Megraud F, O'Morain C, P Gisbert J. Effectiveness and Safety of High-Dose Dual Therapy: Results of the European Registry on the Management of Helicobacterpylori Infection (Hp-EuReg). J Clin Med 2022;11:3544. [PMID: 35743627 DOI: 10.3390/jcm11123544] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Ding SZ, Du YQ, Lu H, Wang WH, Cheng H, Chen SY, Chen MH, Chen WC, Chen Y, Fang JY, Gao HJ, Guo MZ, Han Y, Hou XH, Hu FL, Jiang B, Jiang HX, Lan CH, Li JN, Li Y, Li YQ, Liu J, Li YM, Lyu B, Lu YY, Miao YL, Nie YZ, Qian JM, Sheng JQ, Tang CW, Wang F, Wang HH, Wang JB, Wang JT, Wang JP, Wang XH, Wu KC, Xia XZ, Xie WF, Xie Y, Xu JM, Yang CQ, Yang GB, Yuan Y, Zeng ZR, Zhang BY, Zhang GY, Zhang GX, Zhang JZ, Zhang ZY, Zheng PY, Zhu Y, Zuo XL, Zhou LY, Lyu NH, Yang YS, Li ZS; National Clinical Research Center for Digestive Diseases (Shanghai), Gastrointestinal Early Cancer Prevention & Treatment Alliance of China (GECA), Helicobacter pylori Study Group of Chinese Society of Gastroenterology, and Chinese Alliance for Helicobacter pylori Study. Chinese Consensus Report on Family-Based Helicobacter pylori Infection Control and Management (2021 Edition). Gut 2022;71:238-53. [PMID: 34836916 DOI: 10.1136/gutjnl-2021-325630] [Cited by in Crossref: 4] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
3 Yadollahi B, Valizadeh Toosi SM, Bari Z, Fakheri H, Maleki I, Taghvaei T, Hosseini V, Kazemi A, Shokri-Afra H. Efficacy of 14-day concomitant quadruple therapy and 14-day high-dose dual therapy on H. pylori eradication. Gastroenterol Hepatol Bed Bench 2022;15:172-8. [PMID: 35845300] [Reference Citation Analysis]
4 Alsohaibani F, Peedikayil M, Alshahrani A, Somily A, Alsulaiman R, Azzam N, Almadi M. Practice guidelines for the management of Helicobacter pylori infection: The Saudi H. pylori Working Group recommendations. Saudi J Gastroenterol 2022;0:0. [DOI: 10.4103/sjg.sjg_288_22] [Reference Citation Analysis]
5 Ermolenko EI, Molostova AS, Gladyshev NS. Eradication therapy of helicobacteriosis with probiotics, problems, and prospects. jour 2021. [DOI: 10.31146/1682-8658-ecg-193-9-60-72] [Reference Citation Analysis]
6 Hackett RJ, Preston SL. H.pylori, part II : management in an era of antibiotic resistance. Trends Urology & Men Health 2021;12:18-24. [DOI: 10.1002/tre.818] [Reference Citation Analysis]
7 Li C, Shi Y, Suo B, Tian X, Zhou L, Song Z. PPI-amoxicillin dual therapy four times daily is superior to guidelines recommended regimens in the Helicobacter pylori eradication therapy within Asia: A systematic review and meta-analysis. Helicobacter 2021;26:e12816. [PMID: 34002433 DOI: 10.1111/hel.12816] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
8 Chang YL, Tung YC, Tu YK, Yeh HZ, Yang JC, Hsu PI, Kim SE, Wu MF, Liou WS, Shiu SI. Efficacy of second-line regimens for Helicobacter pylori eradication treatment: a systemic review and network meta-analysis. BMJ Open Gastroenterol 2020;7:e000472. [PMID: 32883715 DOI: 10.1136/bmjgast-2020-000472] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
9 González-hormazábal P, Arenas A, Serrano C, Pizarro M, Fuentes-lópez E, Arnold J, Berger Z, Musleh M, Valladares H, Lanzarini E, Jara L, Castro VG, Camargo MC, Riquelme A. Prevalence of Helicobacter pylori Antimicrobial Resistance Among Chilean Patients. Archives of Medical Research 2021;52:529-34. [DOI: 10.1016/j.arcmed.2021.01.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Scarpignato C, Hunt RH. Acid Suppressant Therapy: a Step Forward with Potassium-Competitive Acid Blockers. Curr Treat Options Gastro 2021;19:94-132. [DOI: 10.1007/s11938-020-00330-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
11 Krzyżek P, Gościniak G, Fijałkowski K, Migdał P, Dziadas M, Owczarek A, Czajkowska J, Aniołek O, Junka A. Potential of Bacterial Cellulose Chemisorbed with Anti-Metabolites, 3-Bromopyruvate or Sertraline, to Fight against Helicobacter pylori Lawn Biofilm. Int J Mol Sci 2020;21:E9507. [PMID: 33327555 DOI: 10.3390/ijms21249507] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
12 Yun J, Wu Z, Qi G, Han T, Zhang D. The high-dose amoxicillin-proton pump inhibitor dual therapy in eradication of Helicobacter pylori infection. Expert Rev Gastroenterol Hepatol 2021;15:149-57. [PMID: 32960107 DOI: 10.1080/17474124.2021.1826306] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
13 Kim HU. Helicobacter pylori Eradication Therapy - Recent Trend in Research. Korean J Helicobacter Up Gastrointest Res 2020;20:210-217. [DOI: 10.7704/kjhugr.2019.0051] [Reference Citation Analysis]
14 Feng XY, Zhang Y, Deng B. Progress in research of high-dose dual therapy as an eradication protocol for Helicobacter pylori infection. Shijie Huaren Xiaohua Zazhi 2020; 28(17): 847-851 [DOI: 10.11569/wcjd.v28.i17.847] [Reference Citation Analysis]
15 Gao CP, Zhang D, Zhang T, Wang JX, Han SX, Graham DY, Lu H. PPI-amoxicillin dual therapy for Helicobacter pylori infection: An update based on a systematic review and meta-analysis. Helicobacter 2020;25:e12692. [PMID: 32314468 DOI: 10.1111/hel.12692] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 14.0] [Reference Citation Analysis]
16 Zhu YJ, Zhang Y, Wang TY, Zhao JT, Zhao Z, Zhu JR, Lan CH. High dose PPI-amoxicillin dual therapy for the treatment of Helicobacter pylori infection: a systematic review with meta-analysis. Therap Adv Gastroenterol 2020;13:1756284820937115. [PMID: 33110448 DOI: 10.1177/1756284820937115] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
17 Saleem N, Howden CW. Update on the Management of Helicobacter pylori Infection. Curr Treat Options Gastroenterol 2020;:1-12. [PMID: 32837180 DOI: 10.1007/s11938-020-00300-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
18 Krzyżek P, Pawełka D, Iwańczak B, Kempiński R, Leśniakowski K, Mégraud F, Łaczmański Ł, Biernat M, Gościniak G. High Primary Antibiotic Resistance of Helicobacter pylori Strains Isolated from Pediatric and Adult Patients in Poland during 2016-2018. Antibiotics (Basel) 2020;9:E228. [PMID: 32370201 DOI: 10.3390/antibiotics9050228] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
19 Arenas A, Serrano C, Quiñones L, Harris P, Sandoval M, Lavanderos M, Sepúlveda R, Maquilón S, Echeverría A, Ríos C, Fuentes-López E, Rojas L, Jorquera A, Pizarro M, Camargo MC, Riquelme A. High prevalence of clarithromycin resistance and effect on Helicobacter pylori eradication in a population from Santiago, Chile: cohort study and meta-analysis. Sci Rep 2019;9:20070. [PMID: 31882676 DOI: 10.1038/s41598-019-56399-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
20 O'Connor A, Liou JM, Gisbert JP, O'Morain C. Review: Treatment of Helicobacter pylori Infection 2019. Helicobacter 2019;24 Suppl 1:e12640. [PMID: 31486235 DOI: 10.1111/hel.12640] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 7.3] [Reference Citation Analysis]
21 Suzuki S, Esaki M, Kusano C, Ikehara H, Gotoda T. Development of Helicobacter pylori treatment: How do we manage antimicrobial resistance? World J Gastroenterol 2019; 25(16): 1907-1912 [PMID: 31086459 DOI: 10.3748/wjg.v25.i16.1907] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 34] [Article Influence: 12.3] [Reference Citation Analysis]